Results 71 to 80 of about 13,218 (206)

‐1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

, 2014
Antiretroviral therapy during pregnancy is recommended to reduce the risk of mother-to-child transmission of HIV and for maternal care management. Physiological changes during pregnancy can affect pharmacokinetics, potentially altering pharmacological ...
P Verboven, CD Zorrilla, Falcon, R, R Wright, Verboven, P, K Brown, Wright, R, Coate, B, B Coate, Kakuda, T N, Yasin, S, Zorrilla, C D, S Yasin, J Mrus, OO Osiyemi, R Falcon, Osiyemi, O O, Baugh, B, Brown, K, Mrus, J, B Baugh, TN Kakuda   +21 more
core   +1 more source

In vitro study of drug-drug interactions of HIV protease inhibitor darunavir on efflux ABC transporters [PDF]

, 2021
Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmacology & Toxicology Student: Dominika Bezděková Supervisor: doc. PharmDr. Lukáš Červený, Ph.D.
Bezděková, Dominika
core  

Post-Marketing Pharmacovigilance Study of Darunavir in the United Kingdom: An Analysis of Adverse Drug Reactions Reported to the MHRA

Pharmacoepidemiology
Background/Objectives: Human immunodeficiency virus (HIV) continues to be a global public health concern. Several antiretroviral drugs have been approved for the treatment, post-exposure, and pre-exposure prophylaxis of HIV. Darunavir (DRV) is a protease
Pono Pono, Vicky Cheng, Victoria Skerrett, Alan M. Jones   +3 more
doaj   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction

, 2011
The present study aimed to investigate potential drug interactions between darunavir and raltegravir in patients treated for HIV infection. We enrolled HIV-infected subjects on darunavir-containing regimens that underwent measurement of plasma darunavir ...
Fabbiani, Massimiliano, Bracciale, Laura, Pierluigi Navarra, Parruti, Giustino, CAUDA R., Prosperi, Mattia, D'ETTORRE G., DE LUCA A., Laura Bracciale, FABBIANI M., BRACCIALE L., PARRUTI G., Massimiliano Fabbiani, NAVARRA P., Cauda, Roberto, Di Giambenedetto, Simona, Enzo Ragazzoni, DI GIAMBENEDETTO S., Giustino Parruti, RAGAZZONI E., Mattia Prosperi, Simona Di Giambenedetto, Gabriella D’Ettorre, Roberto Cauda, Andrea De Luca, De Luca, Andrea, Navarra, Pierluigi, Ragazzoni, Enzo, D'Ettorre, Gabriella, PROSPERI M.   +29 more
core   +1 more source

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).

PLoS ONE, 2019
BackgroundVery few data are available on treatment in HIV Late presenter population that still represents a clinical challenge.MethodsProspective, multicenter, randomized open-label, 2 arm, phase-3 trial comparing the 48-week virological response of two ...
Cristina Mussini, Enrica Roncaglia, Vanni Borghi, Stefano Rusconi, Silvia Nozza, Anna Maria Cattelan, Daniela Segala, Paolo Bonfanti, Antonio Di Biagio, Enrico Barchi, Emanuele Focà, Anna Degli Antoni, Stefano Bonora, Daniela Francisci, Silvia Limonta, Andrea Antinori, Gabriella D'Ettorre, Franco Maggiolo   +17 more
doaj   +1 more source

Profile of darunavir in the management of treatment-experienced HIV patients

, 2009
Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3 ...
Cameron Wolfe, Charles Hicks
core  

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.

, 2012
Objectives: To compare cerebrospinal fluid (CSF) darunavir and ritonavir concentrations in patients receiving darunavir/ritonavir 800/100 mg once daily or 600/100 mg twice daily.
Marinaro, L., D'Avolio, Antonio, D'Avolio, A., Bonora, S., Simiele, M., Yilmaz, Aylin,, Siccardi, Marco, Calcagno, A., Marinaro, Letizia, Simiele, Marco, Cusato, Jessica, Bertucci, R., Bonora, Stefano, Cusato, J., Calcagno, Andrea, Di Perri, G., Yilmaz A, Bertucci R, Siccardi, M., Di Perri, Giovanni   +19 more
core   +1 more source

Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection

Терапевтический архив, 2014
AIM. To evaluate the efficacy of boosted darunavir and atazanavir used in antiretroviral therapy (ARVT) regimens for treatment-naïve HIV-infected patients with low baseline immune parameters and a high viral load. MATERIALS AND METHODS. The investigators
G F Moshkovich, S V Minaeva
doaj  

Reversibility of Neuropsychiatric Adverse Events after Switching to Darunavir/Cobicistat or Doravirine in Men on INSTI-Based Regimen

Viruses
Integrase strand transfer inhibitors (INSTI) are associated with neuropsychiatric adverse events (NPAEs). The aim of this study was to evaluate improvements in NPAEs after switching an INSTI-based regimen to darunavir/cobicistat (DRV/c) or doravirine ...
José Antonio Mata-Marín, Carina Aurora Juárez-Contreras, Mara Soraya Rodríguez-Evaristo, Olivia Concepción Martínez-Carrizales, Ericka Pompa-Mera, Alberto Chaparro Sánchez, Salma Triana-González, Ana Luz Cano-Díaz, Jesús Enrique Gaytán-Martínez   +8 more
doaj   +1 more source